About Cyclica
Cyclica is a Healthcare company based in Toronto (Canada) founded in 2010, and was acquired by Recursion in May 2023. Online AI-interfacedpredictive analytics platform for drug discovery and testing. It operates in the Healthcare and Technology sectors. Cyclica has raised $21.06 million across 7 funding rounds from investors including Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals. Its focus areas include Enterprise Applications, Data as a Service, Industries and Healthcare Data. Its legal entity is CYCLICA INC.
Company details
Online AI-interface predictive analytics platform for drug discovery and testing. It is a biotechnology company that offers a biomolecular analytics platform for proteome docking. It uses proprietary algorithms and databases to improve drug discovery pipelines by identifying risks such as adverse effects, contraindications, and lack of efficacy. It uses multi-channel systems for evaluating and comparing small molecules to predict the reaction with the human body and searches for all proteins that have potential drug-protein interactions. It also offers a proprietary database of bacterial and viral proteomes that can be used to identify new treatments for infectious diseases.
- Headquarters Toronto, Canada
- Stage Acquired
- SectorsHealthcareTechnology
- Website cyclicarx.com
- Social LinkedIn X
- Acquired by Recursion (May 2023)
- Legal Name Cyclica Inc.
- Total Equity Funding$21.06M (USD)
in 7 rounds
- Latest Funding Round$1.81M (USD), Grant
Nov 2022
- InvestorsRecursion Pharmaceuticals
& 9 more
- Acquired byRecursion
(May 2023)
Funding Insights of Cyclica
Cyclica has successfully raised a total of $21.06M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $1.81 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.06M
- Total Rounds 7
- Last Round Grant — $1.81M
- First Round $400,000
(Dec 2013)
- Investors Count 9
All 7 funding rounds of Cyclica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $1.81M | Grant | – | – | |
| Apr 2020 | $16.59M | Series B | – | Drive Capital | |
| Jul 2017 | $2.25M | Series A | – | GreenSky | |
| Sep 2016 | $1.82M | Series A | – | GreenSky | |
| Aug 2015 | Seed | – | – | ||
| Jun 2014 | Seed | – | StartUp Health | – | |
| Dec 2013 | $400,000 | Seed | – | GreenSky | – |
10 investors in total: 10 institutional.
Investors in Cyclica
Cyclica has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on pre-seed and seed stage investments | drivecapital.com | Columbus, United States | ||
Early stage Canadian B2B startups are funded by GreenSky Ventures. | 2015 | greensky.vc | Toronto, Canada | |
| epiccapitalmanagement.ca | ||||
Incubation and venture capital services are offered to high-tech startups. | uniinnovategroup.com | Vancouver, Canada | ||
| hanhaistudio.com | ||||
A cross-border ecosystem builder for Canadian startups targeting China. | 2015 | cc-angels.com | Toronto, Canada | |
Online information platform of health and wellness | 2011 | startuphealth.com | San Francisco, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas | 1935 | chiesi.com | Parma, Italy | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | recursion.com | New York, United States |
Investor details for Cyclica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cyclica
8 people are tracked at Cyclica (2 in leadership, 4 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Jason Mitakidis | Founder | Leadership |
Shane Climie | VP of Corporate Development | Leadership |
Michael T.r. List | Board Director | Board & advisors |
Shoshana Wodak | Scientific Advisor | Board & advisors |
Rick Panicucci | Scientific Advisor | Board & advisors |
Mostafa Analoui | Co-Chairman | Board & advisors |
Jonathan Mcclare | Senior Software Developer | Team |
Ganna Posternak | Drug Discovery Scientist | Team |
Complete people profiles for Cyclica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cyclica
4 dated milestones of Cyclica across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Cyclica is founded.
- Funding First funding round of $400K.
- Funding Latest funding round, Grant, of $1.8M.
- Exit Acquired by Recursion.
Web traffic of Cyclica
Websites that share an audience with Cyclica (cyclicarx.com).
Websites whose visitors overlap most with Cyclica. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| docengage.in | 100% | 1.7K | #8,584,923 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cyclica
Complete news archive for Cyclica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyclica
Cyclica was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Cyclica is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Cyclica is a funded company, having raised a total of $21.06M across 7 funding rounds to date. The company's 1st funding round was a Seed of $400K, raised on Dec 2013.
Online AI-interface predictive analytics platform for drug discovery and testing. It is a biotechnology company that offers a biomolecular analytics platform for proteome docking. It uses proprietary algorithms and databases to improve drug discovery pipelines by identifying risks such as adverse effects, contraindications, and lack of efficacy. It uses multi-channel systems for evaluating and comparing small molecules to predict the reaction with the human body and searches for all proteins that have potential drug-protein interactions. It also offers a proprietary database of bacterial and viral proteomes that can be used to identify new treatments for infectious diseases.
Cyclica has 10 investors. Key investors include Recursion Pharmaceuticals, Gates Foundation, Chiesi Pharmaceuticals, StartUp Health, and Drive Capital.
Cyclica operates through Cyclica Inc..
Yes. Cyclica was acquired by Recursion in May 2023.